The overall goal of this imaging trial is to evaluate crosssectional difference and longitudinal changes of \[18F\]PI-2620, a tau targeted positron emission computed tomography radioligand, in cognitively normal individuals, and subjects with mild cognitive impairment and Alzheimer's disease.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
84
Imaging for evaluating the accumulation of abnormal tau protein in the brain
Asan Medical Center
Seoul, South Korea
Cross-sectional PI-2620 uptake measured by standard uptake value ratio (SUVR)
Cross-sectional PI-2620 uptake measured by standard uptake value ratio (SUVR) in Cognitively normal, Mild Cognitive Impairment and Alzheimer Disease.
Time frame: 60-90 minutes post injection
Changes of PI-2620 uptake over time measured by standard uptake value ratios (SUVR)
Changes of PI-2620 uptake over time measured by standard uptake value ratios (SUVR) in Cognitively normal, Mild Cognitive Impairment and Alzheimer Disease.
Time frame: 60-90 minutes post injection
Correlation between standard uptake value ratio (SUVR) of [18F]PI-2620 positron emission computed tomography and neuropsychiatric test scores
We will evaluate correlation between standard uptake value ratio (SUVR) \[18F\]PI-2620 positron emission computed tomography and scores of neuropsychiatric test
Time frame: 60-90 minutes post-injectio
Correlation between standard uptake value ratio (SUVR) of [18F]PI-2620 positron emission computed tomography and indices of structural MRI
We will evaluate correlation between standard uptake value ratio (SUVR) \[18F\]PI-2620 positron emission computed tomography and indices of structural Magnetic Resonance Imaging including cortical volume, hippocampal atrophy.
Time frame: 60-90 minutes post injection
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.